These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Inability to escalate vinorelbine dose intensity using a daily x3 schedule with and without filgrastim in patients with metastatic breast cancer. Havlin KA; Ramirez MJ; Legler CM; Harris LN; Matulonis UA; Hohneker JA; Hayes DF; Winer EP Cancer Chemother Pharmacol; 1999; 43(1):68-72. PubMed ID: 9923543 [TBL] [Abstract][Full Text] [Related]
44. Phase 2 study of single-agent IV vinflunine as third-line treatment of metastatic breast cancer after failure of anthracycline-/taxane-based chemotherapy. Fumoleau P; Cortés-Funes H; Taleb AB; Chan S; Campone M; Pouget JC; Tubiana-Hulin M; Slabber CF; Caroff-Paraïso I; Alberts AS; Ben Ayed F Am J Clin Oncol; 2009 Aug; 32(4):375-80. PubMed ID: 19487917 [TBL] [Abstract][Full Text] [Related]
45. Feasibility trial of methotrexate-paclitaxel as a second line therapy in advanced urothelial cancer. Bellmunt J; Cos J; Clèries R; Pérez M; Ribas A; Eres N; Murio JE; Margarit C; Baselga J Cancer Invest; 2002; 20(5-6):673-85. PubMed ID: 12197223 [TBL] [Abstract][Full Text] [Related]
46. Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial. Nishiyama H; Yamamoto Y; Sassa N; Nishimura K; Fujimoto K; Fukasawa S; Yokoyama M; Enokida H; Takahashi K; Tanaka Y; Imai K; Shimamoto T; Perini R; Frenkl T; Bajorin D; Bellmunt J Int J Clin Oncol; 2020 Jan; 25(1):165-174. PubMed ID: 31729625 [TBL] [Abstract][Full Text] [Related]
47. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Powles T; Durán I; van der Heijden MS; Loriot Y; Vogelzang NJ; De Giorgi U; Oudard S; Retz MM; Castellano D; Bamias A; Fléchon A; Gravis G; Hussain S; Takano T; Leng N; Kadel EE; Banchereau R; Hegde PS; Mariathasan S; Cui N; Shen X; Derleth CL; Green MC; Ravaud A Lancet; 2018 Feb; 391(10122):748-757. PubMed ID: 29268948 [TBL] [Abstract][Full Text] [Related]
48. Second-Line Chemotherapy for Metastatic Urothelial Carcinoma: Importance of Lymph Node-Only Metastasis as a Prognostic Factor and Construction of a Prognostic Model. Salah S; Lee JL; Rozzi A; Kitamura H; Matsumoto K; Srinivas S; Morales-Barrera R; Carles J; Al-Wardat R; Al-Rabi K; Maakoseh M Clin Genitourin Cancer; 2016 Jun; 14(3):255-60. PubMed ID: 26552764 [TBL] [Abstract][Full Text] [Related]
49. Optimisation of the size variation threshold for imaging evaluation of response in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium treated with vinflunine. Krajewski KM; Fougeray R; Bellmunt J; Pons F; Schutz FA; Rosenberg JE; Salhi Y; Choueiri TK Eur J Cancer; 2012 Jul; 48(10):1495-502. PubMed ID: 22176867 [TBL] [Abstract][Full Text] [Related]
50. A carboplatin-based regimen for the treatment of patients with advanced transitional cell carcinoma of the urothelium. Small EJ; Fippin LJ; Ernest ML; Carroll PR Cancer; 1996 Oct; 78(8):1775-80. PubMed ID: 8859191 [TBL] [Abstract][Full Text] [Related]
51. Efficacy and safety of Vinflunine for advanced or metastatic urothelial carcinoma in routine practice based on the French multi-centre CURVE study. Médioni J; Di Palma M; Guillot A; Spaeth D; Théodore C BMC Cancer; 2016 Mar; 16():217. PubMed ID: 26975779 [TBL] [Abstract][Full Text] [Related]
52. Weekly paclitaxel and carboplatin against advanced transitional cell cancer after failure of a platinum-based regimen. Kouno T; Ando M; Yonemori K; Matsumoto K; Shimizu C; Katsumata N; Komiyama M; Okajima E; Matsuoka N; Fujimoto H; Fujiwara Y Eur Urol; 2007 Oct; 52(4):1115-22. PubMed ID: 17433855 [TBL] [Abstract][Full Text] [Related]
53. Randomised phase III trial of vinflunine plus capecitabine versus capecitabine alone in patients with advanced breast cancer previously treated with an anthracycline and resistant to taxane. Martin M; Campone M; Bondarenko I; Sakaeva D; Krishnamurthy S; Roman L; Lebedeva L; Vedovato JC; Aapro M Ann Oncol; 2018 May; 29(5):1195-1202. PubMed ID: 29447329 [TBL] [Abstract][Full Text] [Related]
54. FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum-Containing Chemotherapy. Ning YM; Suzman D; Maher VE; Zhang L; Tang S; Ricks T; Palmby T; Fu W; Liu Q; Goldberg KB; Kim G; Pazdur R Oncologist; 2017 Jun; 22(6):743-749. PubMed ID: 28424325 [TBL] [Abstract][Full Text] [Related]
55. Vinflunine as second-line treatment in platin-resistant metastatic urothelial carcinoma: a review. Gerullis H; Ecke T; Eimer C; Wishahi M; Otto T Anticancer Drugs; 2011 Jan; 22(1):9-17. PubMed ID: 20948429 [TBL] [Abstract][Full Text] [Related]
56. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial. Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962 [TBL] [Abstract][Full Text] [Related]
57. Phase II trial of vinflunine in relapsed small cell lung cancer. Spigel DR; Hainsworth JD; Lane CM; Clark B; Burris HA; Greco FA J Thorac Oncol; 2010 Jun; 5(6):874-8. PubMed ID: 20521355 [TBL] [Abstract][Full Text] [Related]
58. Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study. Gasparini G; Caffo O; Barni S; Frontini L; Testolin A; Guglielmi RB; Ambrosini G J Clin Oncol; 1994 Oct; 12(10):2094-101. PubMed ID: 7931479 [TBL] [Abstract][Full Text] [Related]
59. Efficacy and Tolerability of Tremelimumab in Locally Advanced or Metastatic Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based Chemotherapy. Sharma P; Sohn J; Shin SJ; Oh DY; Keam B; Lee HJ; Gizzi M; Kalinka E; de Vos FYFL; Ruscica D; Ferro S; Xiao F; Baverel P; Chen CC; Asubonteng K; Morsli N; Dirix L Clin Cancer Res; 2020 Jan; 26(1):61-70. PubMed ID: 31801732 [TBL] [Abstract][Full Text] [Related]
60. Long-term efficacy and safety outcomes of modified (simplified) MVAC (methotrexate/vinblastine/doxorubicin/cisplatin) as frontline therapy for unresectable or metastatic urothelial cancer. Necchi A; Mariani L; Giannatempo P; Raggi D; Farè E; Nicolai N; Piva L; Biasoni D; Catanzaro M; Torelli T; Stagni S; Maffezzini M; Pizzocaro G; De Braud FG; Gianni AM; Salvioni R Clin Genitourin Cancer; 2014 Jun; 12(3):203-209.e1. PubMed ID: 24394493 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]